Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P50995

UPID:
ANX11_HUMAN

ALTERNATIVE NAMES:
56 kDa autoantigen; Annexin XI; Annexin-11; Calcyclin-associated annexin 50

ALTERNATIVE UPACC:
P50995; B4DVE7

BACKGROUND:
The protein Annexin A11, with alternative names such as 56 kDa autoantigen and Annexin-11, is essential for cytokinesis, binding to calcyclin in a calcium-dependent manner. This protein's function is critical for the terminal phase of cell division, indicating its pivotal role in cellular replication and health.

THERAPEUTIC SIGNIFICANCE:
Given Annexin A11's involvement in Amyotrophic lateral sclerosis 23 and muscle weakness diseases, its study offers promising avenues for drug discovery. The protein's role in these conditions suggests that targeting Annexin A11 could lead to innovative treatments for neurodegenerative diseases and disorders affecting muscle function.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.